FMS-like tyrosine kinase 3 (FLT3) is an attractive target for acute myeloid leukemia. Recent
studies have suggested that the application of small-molecule kinase inhibitors is a …

Research has shown that FMS-like tyrosine kinase 3 (FLT3) may be a vital drug target for
acute myeloid leukemia (AML). However, even though the clinically relevant F691L …

Objective. FMS‐like tyrosine kinase 3 (FLT3) is an attractive therapeutic target in acute
myeloid leukemia. Unfortunately, secondary FLT3 mutations that developed resistance to …

FMS‐like tyrosine kinase 3 (FLT3) has been found to be mutated in~ 30% of acute myeloid
leukaemia patients. Small‐molecule inhibitors targeting FLT3 that are currently approved or …

Background Mutations in the FMS-like tyrosine kinase 3 (FLT3) are associated with
uncontrolled cellular functions that contribute to the development of acute myeloid …

Introduction: Acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutation
is associated with poor prognosis with a high risk of relapse after therapy and reduced …

FMS-like tyrosine kinase 3 (FLT3) serves as an important drug target for acute myeloid
leukemia (AML), and gene mutations of FLT3 have been closely associated with AML …

Activating mutations in FMS-like tyrosine kinase 3 (FLT3) occur in 25% of acute lymphoid
and 30% of acute myeloid leukaemia cases. Therefore, FLT3 is a potential therapeutic target …

More than one-third of patients with acute myeloid leukemia (AML) harbor aberrant
mutations in Fms-like tyrosine kinase 3 (FLT3). Among them, the internal tandem duplication …

FMS-like tyrosine kinase 3 (FLT3) inhibitors have shown activity in the treatment of acute
myelogenous leukemia (AML). Secondary mutations in target kinases can cause clinical …